



30 April 2025

Notification of Investor Briefing

Control Bionics Limited (ASX:CBL), an Australian leader in Electromyography medical device technology, is pleased to announce that it will on 30 April 2025 hold an investor webinar following release of the Company's quarterly results and Appendix 4C.

Control Bionics CEO, Jeremy Steele, will provide a short presentation which will then be followed by Q&A.

Webinar Details: 12.30pm Melbourne time, Wednesday 30 April 2025.

Link to register to attend the presentation:

<https://zoom.us/meeting/register/rS7EFYk3QT6dQNO06r0Ltq>

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that wish to join by phone.

Questions can be submitted on the day or sent in advance to joe@lynxadvisors.com.au

This announcement is authorised by Control Bionics CEO, Jeremy Steele.

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time. DROVE recently got approved by the TGA as a Class I medical device.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip®. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.



Investors and Media

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley - Company Secretary
brettcrowley@controlbionics.com

Investor Relations:

Joe Durak
Executive Director & Founder
Lynx Advisors
joe@lynxadvisors.com.au
+61 414 465 582

Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria 3121, Australia
T: +61 3 9897 3576
W: www.controlbionics.com
ABN: 45 115 465 462

For further information visit the website: <https://www.controlbionics.com/>